PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Published: August 2016
No. of Pages: 416
    ReportsandReports

Coronary artery disease (CAD), which precipitates acute coronary syndrome (ACS), is the most common type of cardiovascular disease (CVD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). At present, the cardiovascular (CV) drug market is well established and boasts a multitude of branded and generic drug choices to treat the major conditions associated with ACS: thrombosis (fibrinolytics, anticoagulants, and antiplatelets), hypercholesterolemia/atherosclerosis (statins and PCSK9 inhibitors), and hypertension (renin angiotensin aldosterone system (RAAS) inhibitors and beta blockers). Due to this range of sub-indications and the recent increase in disease prevalence, it is evident that ACS represents a potentially lucrative market for Big Pharma to explore.

It is estimated that sales of acute coronary syndrome (ACS) therapeutics to be approximately $7.8B across the 7MM in 2015, including the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2015 base year 10% of market share were attributed to the acute phase sales ($714M) and 90% to the chronic phase ($7.0B). By 2025, the ACS market to grow at a strong Compound Annual Growth Rate (CAGR) of 4.6%, reaching sales of $12.1B by the end of the forecast period. This is mainly attributed to the chronic phase growth, which is forecast to reflect a CAGR of 5.0%, reaching $11.4B in sales by 2025 (94% of market share).

As per Michela J. McMullan, Analyst: “At present, a large proportion of patients with clinical atherosclerotic cardiovascular disease cannot reach guideline recommended levels of LDL-C with the standard of care therapies, which leads to recurrent ACS events.

Major drivers of ACS market growth over the forecast period are the:

• Launches of the first PCSK9 inhibitors, Repatha (evolocumab) and Praluent (alirocumab), in the US (2015), EU (2015), and Japan (2016); and positive results from their cardiovascular (CV) outcomes trials.

• Launch of first-in-class lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor/ adenosine monophosphate-activated protein kinase (AMPK) activator, ETC-1002, in 2021.

• Increase in the global prevalence of ACS.

The report “PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025” provides overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report provides the following analysis:

• Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.

• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

• Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Amgen, AstraZeneca, Bristol-Myers Squibb, Cerenis Therapeutics, CSL Limited, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, (Johnson & Johnson), The Medicines Company, Merck, Pfizer, Sanofi

Published By: GlobalData
Product Code: GlobalData36367


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: